# Ionis Pharmaceuticals

Source: https://onco.cc/companies/ionis/  
OnCo record `ionis` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ionis is the Carlsbad company that made antisense oligonucleotides into medicines; its cancer programmes, including the clusterin antisense custirsen developed with OncoGenex and the STAT3 antisense danvatirsen, reached late trials without approval.

## Summary

Ionis Pharmaceuticals, founded in 1989 as Isis Pharmaceuticals and based in Carlsbad, California, pioneered antisense oligonucleotide drugs, with approvals in spinal muscular atrophy, transthyretin amyloidosis and other rare diseases through partners. In oncology it co-developed custirsen (OGX-011), whose phase 3 trials failed, and tested the STAT3 antisense danvatirsen with checkpoint inhibitors through AstraZeneca. ClinicalTrials.gov lists Ionis as lead sponsor of a phase 3 cancer trial.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Ionis Pharmaceuticals, Inc.; Isis Pharmaceuticals
- Tags: ctgov-sponsor
- HQ: Carlsbad, CA
- Type: biotech
- Website: https://www.ionispharma.com

## Sources

- Official website: https://www.ionispharma.com
- ClinicalTrials.gov: trials led by Ionis Pharmaceuticals, Inc.: https://clinicaltrials.gov/search?lead=Ionis%20Pharmaceuticals%2C%20Inc.
- Wikidata: https://www.wikidata.org/wiki/Q22079531

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [Oligonucleotide therapeutics](https://onco.cc/technologies/antisense-sirna/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/ionis.json